A smaller loss on flat revenue

How did Proteome Sciences (LSE:PRM) reduce its half-year loss when total Revenue barely moved? The interim results published in September 2026 show that the answer lies in a change in revenue mix towards higher-margin reagent income, alongside tighter cost control, while the services side of the Business waits for a larger order book to convert into reported sales.

What the company does

Proteome Sciences is an AIM-quoted life sciences company specialising in proteomics, the large-scale analysis of proteins. It earns money in two ways. Its laboratories in Frankfurt, which hold GCLP accreditation for work supporting clinical trials, and San Diego provide mass spectrometry-based protein analysis services to pharmaceutical and biotechnology clients. It also earns sales and royalties from its TMT reagents, chemical tags used to compare protein levels across multiple samples in a single experiment. Stefan Fuhrmann is finance director, alongside executive chairman Christopher Pearce.

The interim results and a new contract

On 16 September 2026, the company published results for the six months to 30 June 2026. It reported revenue of £1.87m, compared with £1.86m a year earlier. Within that, proteomics services revenue fell 17% to £0.89m, which the company attributed to timing, while TMT reagent sales and royalties rose 24% to £0.98m.

Gross profit increased to £0.44m from £0.32m, operating costs fell 11% to £3.11m and the operating loss narrowed to £1.24m from £1.62m. The net loss improved by 35% to £1.40m. Cash stood at £1.10m at the end of June, up from £0.78m at the end of 2025, helped by a share placing completed in January 2026.

A day earlier, on 15 September 2026, Proteome Sciences announced a further GCLP chemoproteomics contract with an unnamed major biopharmaceutical client, the third for the same protein across the client's global phase 1 and phase 2 trials. The value was not disclosed. The company said sample shipments are expected later in 2026, with most of the work completed in 2027. Chief commercial officer Richard Dennis said the company continues "to see Demand from major biopharma clients in the US and Europe for GCLP grade protein assays".

Reading the numbers

The company reported that orders received in the first half rose 32%, with their combined value nearly equal to all services revenue for 2025. Executive chairman Christopher Pearce said that with a healthy order book in place, the company is confident full-year services revenue in 2026 will show a significant increase over 2025. This suggests management expects the services decline in the first half to reverse, although the timing of sample deliveries from clients lies partly outside its control.

The improvement in Gross Profit appears linked to the higher share of reagent income, which typically requires less laboratory capacity than bespoke services work. In San Diego, the company said discovery projects could lead to future work on targeted assays.

Risks and developments to watch

Proteome Sciences remains loss-making, and its cash balance of £1.10m is modest relative to a half-year operating loss of £1.24m. The directors confirmed they consider the company has adequate resources, but funding headroom remains an area to watch. Revenue is concentrated among a limited number of large pharmaceutical clients, and contract values are often undisclosed, making forecasting difficult. Conversion of the order book into revenue during the second half, along with continued reagent Royalty growth, are the key indicators ahead.

The board is also changing: Helen Spice, a chartered Accountant and former KPMG chief financial officer, was appointed as a non-executive director on 16 September, with Dr Ursula Ney departing.

Conclusion

Proteome Sciences narrowed its loss because reagent income grew, gross profit improved and costs fell, not because overall revenue increased. The second half will show whether the larger services order book delivers the revenue growth management expects.